The latest overall survival analysis of the HEAT Study, which is evaluating ThermoDox and radiofrequency ablation in hepatocellular carcinoma, showed that a subgroup of patients demonstrated an average 58 percent improvement in overall survival.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
